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Abstract 
Cytokines and chemokines, hepatitis C virus (HCV) infection-induced, participate in viral control and 
liver damage. The complex cytokine network, operating during initial infection allows a coordinated 
and effective development of innate and adaptive immune responses. “HCV interferes with cytokines 
at various levels and escapes immune response by inducing a T helper (Th)2/T cytotoxic 2 cytokine 
profile”. A predominance of the Th1 immune response (and related cytokines) has been evidenced in 
chronic hepatitis C infection and in extrahepatic manifestations. Interferon (IFN)-γ and IFN-γ-inducible 
chemokine (C-X-C motif) ligand (CXCL)9, -10 and -11 recruit inflammatory infiltrates into the liver 
parenchyma due to the incapability to control the infection process, resulting in extensive liver damage 
and liver cirrhosis. “The most important systemic HCV-related extrahepatic diseases — mixed 
cryoglobulinemia, lymphoproliferative disorders, diabetes and autoimmune thyroid disorders — are 
associated with a complex dysregulation of the cytokine/chemokine network and involve pro-
inflammatory and Th1 chemokines. The therapeutical administration of cytokines such as IFN-α may 
result in viral clearance during persistent infection and reverts this process” reducing circulating 
CXCL10 levels. “Several studies have reported interleukin (IL)-28B polymorphisms, and circulating 
CXCL10, may be prognostic markers for HCV treatment efficacy in HCV infection”. Other studies 
have also shown that HCV clearance by directly acting antiviral agents therapy decreases circulating 
CXCL10 levels. “Theoretically agents that selectively neutralize CXCL10 could increase patient 
responsiveness to traditional IFN-based HCV therapy”, simultaneously reducing inflammatory immune 
cell activation.  
 
Keywords: chemokines, CXCL10, cytokines, IFN inducible chemokines, HCV extrahepatic 
manifestations, hepatitis C chronic infection, hepatitis C virus.  
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1. INTRODUCTION 
 
Chemokines are small proteins participating in leukocyte trafficking [1]; they are divided into two 
major (C-X-3-C motif and C-X-C motif) and two minor (C-C motif and C motif) subfamilies [2-4]. 
Only one non-conserved aminoacid residue, that separates the N-terminal cysteines, is present in the C-
X-C subfamily. “Interferon (IFN)-γ-inducible C-X-C chemokines [IFN-γ-induced protein 10 (IP-
10/CXCL10), monokine induced by IFN-γ (Mig/CXCL9), and IFN-inducible T-cell chemoattractant (I-
TAC/CXCL11)]”, are members of the C-X-C subfamily. These C-X-C chemokines are preferentially 
expressed on T helper (Th)1 lymphocytes [5-7]. These chemokines bind to C-X-C chemokine receptors 
(CXCR), and activate “CXCR3 which is a seven trans-membrane-spanning G protein-coupled receptor 
expressed in activated Th1 lymphocytes [8], Natural Killer (NK) and B cells, and other cells [9,10]”.  
In response to IFN-γ, CXCL10 is released by different cells, as activated neutrophils, monocytes, 
epithelial cells, endothelial cells [11,12] and “attracts activated Th1 lymphocytes into the area of 
inflammation; its expression is associated with a Th1 immune response [13-15] and is increased in 
infectious, inflammatory [16,17] and autoimmune diseases [2], and cancer”. Participating in leukocyte 
homing to inflamed tissues, CXCL10 worsens inflammation leading to a significant tissue damage [2]. 
Increased concentration of CXCL10 in biological fluids or tissues is a marker of Th1 orientated T-cells 
immune response. Activated Th1 lymphocytes secrete tumor necrosis factor (TNF)-α and IFN-γ, that 
stimulate CXCL10 release from the above reported cells, reiterating the immune cascade by an 
amplification feedback loop [18]. 
Organ specific autoimmune diseases, as type 1 diabetes [19-21], Graves’ disease [22,23] or Graves’ 
ophthalmopathy, autoimmune thyroiditis (AT) [24], or rheumatological disorders, as systemic lupus 
erythematosus, rheumatoid arthritis, systemic sclerosis [25-27], psoriasis or psoriatic arthritis [28], 
show an increased tissue and/or serum CXCL10 expression.  
The Th1 immune response is also involved in various neoplastic disorders [29-32], and in the 
pathogenesis of infectious diseases [33-36], as of those by Mycobacterium tuberculosis [34], 
Toxoplasma gondii [35], sepsis [37], and others. 
 
2. Hepatitis C 
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Hepatitis C is caused by the hepatitis C virus (HCV), affecting 150–200 million people worldwide [38]. 
HCV causes acute symptoms in 15% of cases [39,40]. About 85% of the subjects exposed to HCV 
develop a chronic infection (CHC) [40-42], and (among them) about 20% of patients develop cirrhosis 
(over 30 years; overall in patients with risk factors, such as coinfection with hepatitis B, schistosoma, 
or HIV, use of alcoholics and male gender). HCV cirrhosis is associated with a 20-fold greater risk of 
hepatocellular carcinoma (HCC) [43-45]. CHC is also associated with extrahepatic manifestations 
(HCV-EHMs); “the most common is mixed cryoglobulinemia (MC; usually the type II form; an 
inflammation of small and medium-sized blood vessels)”. Other HCV-EHMs are AT, diabetes mellitus, 
Sjögren's syndrome, porphyria cutanea tarda, and B-cell lymphoproliferative disorders [40,46].  
 
3. Innate immunity in CHC 
Activation of innate immune pathways in hepatocytes following HCV infection leads to infiltration of 
anti-viral immune competent cells into the liver [47]. 
The recognition of foreign motifs of DNA, RNA, or protein (namely “pathogen associated molecular 
patterns”) by innate pattern recognition receptors (PRRs) activate cellular innate immune pathways. 
The innate immune response is determined by the interplay of PRRs [belonging to three PRRs families: 
“Toll-like receptors (TLRs), “retinoic acid inducible gene 1 (RIG-I)-like receptors” (RLRs), or Nod-
like-receptors (NLRs)”], and their downstream signaling pathways. 
The positive sense HCV RNA is recognized by two different PRRs in the hepatocyte: RIG-I and TLR3 
[48]. TLR3 recognizes longer double-stranded RNAs (generated during viral replication) [48]; 
activated TLR3 binds the signaling adaptor “Toll/interleukin (IL)-1 receptor (TIR)-domain-containing 
adapter-inducing IFN-β (TRIF)” [49]. Double-stranded, 5′ tri-phosphate RNAs containing poly-U or 
poly-A motif binds to RIG-I and activates the mitochondrial antiviral-signaling protein (MAVS) 
signaling adaptor [49]. TRIF and MAVS signaling activate nuclear factor (NF)-κB, C/EBP-β, and IFN 
regulatory factors (IRFs), which induce gene transcription [49]. These transcription factors have 
binding sites in the CXCL10 promoter. It has been shown that HCV can induce NF-κB binding to this 
site in TLR3-expressing hepatocytes [48]. 
In hepatocytes HCV activation of IRF3 and IRF7 can induce “type I IFNs (IFN-α and IFN-β) and type 
III IFNs (IL-28A, IL-28B, IL-29)” with anti-viral activity. These cytokines amplify cytokines and 
chemokines response in liver cells [activating Janus kinases (JAKs) and other signal transducer and 
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activator of transcription (STAT) proteins] [50]. Activation of JAK-STAT signaling [through the 
binding of STAT dimers to IFN-stimulated response elements (ISREs) or IFN-γ activation site 
elements in their promoters] [50] induces IFN-stimulated genes (ISGs). Type II IFN or IFN-γ 
(produced by infiltrating NK cells, CD8+ T cytotoxic (Tc) cells, and CD4+ Th1 cells) can also induce 
STAT1-signaling through these elements [50]. The CXCL10 promoter can respond to all three types of 
IFN, containing putative ISREs and putative STAT-binding sites [51].  
The synthesis of anti-viral type-1 IFN [52] is the primary cell defense mechanism at the beginning 
of the infection; IFN-α/β can stop viral replication and spread to other cells. However, despite type-
1 IFN activation, HCV, at least partially, does not respond to IFN-α/β, and may replicate in the 
liver; in fact, nonstructural proteins E2, NS3, and NS5A may stop the transcription and “expression 
of IFN-α/β-induced genes” [53]. 
NK and Natural killer T (NKT) cells exert their anti-viral action via: a- secretion of IFN-γ [54]; b- 
direct mechanisms [54]; c- facilitating maturation of dendritic cells (DCs) and development of 
Th1/Tc1 responses [55]. However, HCV attempts to escape the immune reaction blocking NK and 
NKT cells functions (through the “interaction between HCV E2 protein and NK-cell CD81 
molecule”) [56]. 
During HCV infection the interaction of HCV structural proteins with TLR-2 in monocytes can 
lead to a decrease in IFN-α production [57], inducing IL-10 and inhibiting IL-12 and IFN-α 
secretion in DCs [58]; also an increased IFN-α production in patients not responding to exogenous 
IFN-α has been shown [59].  
Several studies have demonstrated that a “progressive liver injury in CHC is associated with 
increased expression of Th1-associated cytokines” [60]. 
 
4. Adaptive response in CHC 
HCV CD4+ T cells are determinant in adaptive response. These cells secrete Th1 cytokines (as 
IFN-γ) that induce the recruitment of neutrophil and macrophage, leading to inflammatory 
response. However, HCV CD4+ T cells release also Th2 cytokines (IL-10, IL-4), which confine 
Th1 immune response and induce the humoral response [61]. In HCV infections evolving to 
resolution a strong and sustained, CD4+ T cell specific Th1 response is present [62]. When HCV 
infection evolves to the chronic phase “a weak CD4-T specific response, and scarce type-1 cytokine 
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production”, are evident [63]. 
CD8+ Tc are able to clear viruses through type-1 cytokines (IFN-γ, TNF-α), and/or apoptosis-
related cytolytic mechanisms. In CHC specific Tc show reduced type-1 cytokine secretion and have 
anergic characteristics [64]. It has also been shown that, in CHC, regulatory T cells can release IL-
10 and transforming growth factor (TGF)-β, inhibiting cytokine synthesis in T cells and 
proliferation [65].  
T cells are determinant in the regulation of humoral responses secreting cytokines. Such humoral 
responses are not able to control CHC, however, are important in the pathogenesis of HCV-EHMs 
[66].  
 
5. CXCR3 chemokines and chronic HCV infection 
In CHC, “lymphocytes infiltrating hepatitis C-infected liver express elevated levels of CCR5 and 
CXCR3, and the CXCR3 ligands CXCL10 and CXCL9 are up-regulated on sinusoidal endothelium 
[67]. In vitro, human hepatic sinusoidal endothelial cells”, stimulated with IFN-γ in combination with 
TNF-α secreted CXCL10 and CXCL9. These results suggested that intrahepatic production of IFN-γ 
drives the increased expression of CXCL10 and CXCL9, promoting “the continuing recruitment of 
CXCR3-expressing T cells into the hepatic lobule” in CHC [67].   
A further study evaluated the expression of CXCL10 both in serum and in the liver of patients with 
CHC. Unlike in chronic hepatitis B or in liver disorders unrelated to viral infections, in CHC CXCL10 
expression was highly correlated with the amount of transcripts for IFN-γ [68]. 
It was also shown that hepatocytes expressed CXCL10, but not other cell types in the liver. The 
predominant CD8 T lymphocytes present in the infiltrate of liver lobule were nearly uniformly 
CXCR3-positive, and the CXCL10 mRNA expression correlated with lobular necroinflammatory 
activity, indicating that HCV can induce CXCL10 in the hepatocytes, being determinant in the 
pathogenesis of CHC [69]. 
In human hepatocyte-derived cells it was demonstrated that NS5A and core proteins, alone or acting 
synergistically with cytokines, are able to upregulate CXCL10 and CXCL9 genes [70].  
The induction of CXCL10 secretion by HCV in hepatocytes has been confirmed in other studies 
[71,72]. 
It has also been shown that “intrahepatic CXCL10 mRNA expression levels were significantly 
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associated with lobular necroinflammatory grade and HCV genotype 1” [73]. 
Moreover CXCL10 plasma levels were significantly elevated in patients with advanced fibrosis, 
suggesting that CXCR3-associated chemokines could be considered noninvasive markers of hepatic 
fibrosis in HCV genotype 1-infected patients [74]. Other studies confirmed that the CXCR3 
chemokines are the most significantly expressed ones in CHC probably being determinant in 
positioning T cells in the liver [75,76]. Also other studies confirmed that CXCL10 is a marker of liver 
fibrosis in CHC [77-79]. 
Furthermore it has been suggested that CXCL10 (induced by HCV) leads to increased hepatocyte 
turnover and the development of fibrosis, cirrhosis, and HCC [80].  
HCV antiviral therapy effect on CXCL10 has been also evaluated. In a first study it was shown that 
after successful treatment of CHC, the serum level of CXCL10 decreased to the same level as in 
healthy volunteers [81].  
Before, during, and after antiviral therapy chemokine levels were tested in 29 patients infected with 
HCV genotype 1 [82]. CXCL10 and CXCL9 were elevated, and decreased upon successful antiviral 
therapy. Patients with HCV who subsequently became non-responders (NR) to therapy had the highest 
baseline level of CXCL10 (assayed before the start of antiviral treatment); suggesting that CXCL10 
plasma concentrations could predict responsiveness or nonresponsiveness to antiviral therapy with 
pegylated IFN (PEG-IFN), with or without ribavirin (RBV) [82]. 
“To analyse the possible association of serum CXCL10 levels with different outcomes to antiviral 
therapy, serum CXCL10 levels were determined in 137 CHC patients treated with PEG-IFN plus RBV. 
Pretreatment serum CXCL10 levels in patients with sustained viral response (SVR) were significantly 
lower than in NR (332.4 versus 476.8 pg/mL). Serum CXCL10 concentrations significantly decreased 
in patients with SVR but not in NR. In patients with genotype 1, baseline viral load and pretreatment 
serum CXCL10 levels were identified as predictive factors of SVR [83]. 
In a further study treatment with PEG-IFN α-2b plus RBV of CHC patients increased 
CCR5(high)/CXCR3(high) expressing CD8+ cells frequency in peripheral blood and decreased 
CXCL10/CCL3 serum concentration. Achievement of viral control was associated with an increase in 
CXCR3(high) expressing CD8+ cells during treatment” [84]. 
RBV “improves the kinetics of the early response to therapy in patients with an adequate initial 
response to PEG-IFN. Patients administered with the combination therapy had serum CXCL10 higher 
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at 12 hours than those given with PEG-IFN only; the difference was greatest in patients with an 
adequate first-phase decrease in HCV RNA. CXCL10-induction correlated with first- and second-
phase kinetics and with RBV serum concentrations” [85]. 
Also other studies confirmed that pretreatment CXCL10 levels predicted for both early virological 
response (EVR) and SVR, to IFN-α and RBV, and may be useful to evaluate candidates for therapy 
[86-92]. 
It has been also shown that serum CXCL10 level is a predictor for SVR in HCV-4-infected patients. 
The baseline CXCL10 level was significantly lower in responders among HCV genotype-4 patients 
[93,94]. 
“Polymorphisms of the IL-28B gene are strongly associated with SVR in patients with CHC treated 
with PEG-IFN and RBV. CXCL10 levels were evaluated in pretreatment serum from 115 NR and 157 
sustained responders in the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C 
cohort and resulted lower in sustained responders with respect to NR [95]. The positive predictive 
value of low CXCL10 levels (< 600 pg/mL) for SVR was 69%, whereas the negative predictive value 
of high CXCL10 levels (> 600 pg/mL) was 67%. Whether the combination of pretreatment CXCL10 
levels with IL-28B genotype can be considered predictors of treatment response was evaluated. The IL-
28B polymorphism rs12979860 was tested. The CC, CT, and TT genotypes were shown in 30%, 49%, 
and 21% of patients, respectively, with corresponding SVR rates of 87%, 50%, and 39%. Serum 
CXCL10 levels within the IL-28B genotype groups provided additional information regarding the 
probability of SVR (P < 0.0001). CT carriers with low CXCL10 had 64% SVR versus 24% with high 
CXCL10. Similarly, a higher SVR rate was identified for TT and CC carriers with low versus high 
CXCL10 (TT, 48% versus 20%; CC, 89% versus 79%). The Authors concluded that when IL-28B 
genotype is combined with pretreatment serum CXCL10 measurement, the predictive value for 
discrimination between SVR and nonresponse is significantly increased, particularly in non-CC 
genotypes” [95]. 
Also other studies confirmed that CXCL10 is a useful biomarker to predict treatment failure in HCV 
patients in combination with IL-28B [96-100]. 
HCV treatment is changing over time from IFN-α-based therapies to IFN-α-free regimens comprising 
directly acting antiviral agents (DAAs), showing increased efficacy and tolerability in clinical trials. 
Upon DAA therapy treatment failure can commonly occur owing to virologic relapse; however, the 
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reason why relapse occurs or whether certain subjects are more prone to recurrent viremia is still not 
known. “A clinical trial using the DAA sofosbuvir plus ribavirin (SOF/RBV) performed detailed 
mRNA expression analysis in liver and peripheral blood from patients who achieved either a SVR or 
relapsed. On-treatment viral clearance was accompanied by rapid downregulation of ISGs in liver and 
blood, independently from treatment outcome. Analysis of paired pretreatment and end of treatment 
(EOT) liver biopsies from SVR patients showed that viral clearance was accompanied by decreased 
expression of type II and III IFNs, but unexpectedly increased expression of the type I IFN IFNA2. The 
above reported data indicate that restoration of type I intrahepatic IFN signaling by EOT may facilitate 
HCV eradication and prevention of relapse after withdrawal of	  SOF/RBV” [101].  
Also other studies confirmed that HCV clearance by DAAs therapy decreases circulating CXCL10 
levels [102-104].  
 
6. CXCR3 chemokines and HCV-associated MC  
MC is commonly considered a systemic small vessel vasculitis [105,106] and, considering the presence 
of polyclonal or oligo-monoclonal immunoglobulin M, two types are known (type 2, IgG + monoclonal 
IgM; and type 3, IgG + polyclonal IgM).  
“MC is considered a ‘benign’ B-cell lymphoproliferative disease, as the expansion of rheumatoid 
factor-producing B-cells is its underlying disorder” [107]. It is suggested that a determinant role in the 
pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia (HCV+MC) is the inhibition of 
B-cells apoptosis, that causes their progressive accumulation [107]. 
Different studies have shown [108,109] that “the evolution of HCV infection toward MC is associated 
with a strong Th1 response”.   
Moreover, we have demonstrated that “circulating CXCL10 and CXCL11 are higher in patients with 
HCV+MC than in chronic HCV patients”, and they are more strongly elevated in patients with 
HCV+MC with respect to healthy subjects, especially if active vasculitis is present. Circulating IFN-γ 
and CXCL11 are markedly associated, suggesting the importance of a Th1 immune response in the 
pathogenesis of HCV+MC [110-116].  
On the whole CXCL10 and CXCR3 seem to be implicated in the pathogenesis of HCV+MC. “The 
secretion of CXCL10 by CD4+, CD8+ and NKT cells depends on IFN-γ, which is itself mediated by 
the IL-12 cytokine family. Stimulated by IFN-γ, CXCL10 is secreted by several cell types as 
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lymphocytes, hepatocytes, endothelial cells, fibroblasts, etc.” In tissues, recruited Th1 lymphocytes 
could be associated with an increased production of IFN-γ and TNF-α, which in turn stimulates 
CXCL10 secretion from the cells, perpetuating the autoimmune process through an amplification 
feedback loop. High levels of CXCL10 in circulation have been found in HCV+MC, especially in 
patients with clinically active vasculitis. Furthermore, HCV+MC patients with AT have higher levels 
than those without AT. 
 
7. Thyroid disorders associated with CHC 
“Many studies have recently confirmed an association of HCV infection with autoimmune thyroid 
disorders (AITD) in adults [117,118], and children [119]. The thyroid disorders observed in CHC are 
characterized by a higher risk of AT in females, increased serum levels of anti-thyroperoxidase 
antibodies, and increased risk of hypothyroidism. Recently several studies have confirmed a high 
frequency of AT in patients with MC and CHC [120].   
An elevated prevalence of papillary thyroid cancer (PTC) has been observed in patients with CHC, and 
more recently in MC patients, overall in the presence of AT [18,121]. The increased prevalence of PTC 
in CHC and MC is clinically relevant as approximately 10-30% of these patients may have an 
aggressive disease, requiring systemic treatments”. 
The immuonopathogenesis of thyroid disorders associated with CHC and MC has been studied in many 
papers. Patients with AT have elevated levels of CXCL10, CXCL9, CXCL11, especially if 
hypothyroidism is present, and the Th1 immune response is implicated in the induction of AT, Graves’ 
disease and Graves’ ophthalmopathy [116]. Moreover, HCV has been demonstrated to be present in the 
thyroid of chronically infected patients [122,123]. 
On these bases, it has been hypothesized that HCV thyroid infection could upregulate CXCL10 
expression and secretion in infected thyrocytes recruiting Th1 cells, that secrete IFN-γ and TNF-α 
inducing a further CXCL10 release by thyrocytes, initiating and perpetuating the immune cascade, that 
leads into the appearance of AT in genetically predisposed subjects [124,125]. Many studies have 
confirmed the above reported theory and have shown elevated serum CXCL10 in patients with CHC, 
and MC, in the presence of AT [126]. 
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Interestingly, the fact that in MC patients “circulating CXCL10 is significantly higher in presence of 
AT, compared to patients without thyroiditis”, while CCL2 (the prototype Th2 chemokine) is 
comparable, indicates that the Th1 CXCL10 chemokine is specifically linked with the appearance of 
AT in these patients [124,127]. 
The above reported data highlight the importance of the Th1 immune response in the initiation and 
perpetuation of AT in patients with CHC and MC, in agreement with the observations in other 
autoimmune disorders. 
Interestingly, the increasing prevalence of HCV somehow parallels the increasing prevalence of 
autoimmune thyroid disease that has been documented by other studies [128,129].  
 
8. The role of cytokines in the therapy of CHC and MC 
IFN-α is the cytokine commonly used in the treatment of CHC. PEG-IFN-α combined with RBV causes 
SVR in 50% of patients [130]. The principal effect of IFN-α is anti-viral, but it has an 
immunemodulatory action favoring Th1/Tc1 response restoration, too [131]. RBV, a wide-spectrum 
antiviral agent administered in combination therapy for CHC, has immunomodulatory effects inducing 
type-1 IFN production [132]. A sustained viral load reduction, with antiviral drugs, facilitated specific T 
response recovery and the production of type-1 cytokines in CHC [133,134]. 
A reduced intrahepatic inflammation is obtained also by the administration of Th1-inducing (as IL-12) 
[135] or anti-inflammatory (as IL-10) cytokines [136]; even if, such therapies remain experimental. 
Very recently, different “genome-wide association studies identified single nucleotide polymorphisms 
near the IL-28B region (rs12979860 and rs8099917) that are strong pretreatment predictors of early 
viral clearance and SVR in patients with genotype 1 HCV infection [137,138]. IL-28B encodes IFN-λ3, 
a type III IFN involved in host antiviral immunity. IFN-λ3 up-regulates ISGs (similarly to IFN-α and 
IFN-β) but via a different receptor; moreover IFN-λ3 affects the adaptive immune response [139]. 
Further investigations have implicated IL-28B in the spontaneous resolution of acute infection versus 
the development of chronic HCV infection, suggesting that IL-28B may be a key factor involved in host 
immunity against HCV [137,138,140]. 
Clinical studies assessing safety and efficacy in the treatment of HCV with exogenous IFN-λ3 suggest 
that IFN-λ3 treatment inhibits HCV, and hepatotoxicity in both healthy volunteers and HCV-infected 
patients has been shown” [141,142].  
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Conclusion 
Cytokines and chemokines, induced by infection with HCV, are implicated in viral control and liver 
damage. A coordinated and effective development of innate and adaptive immune responses is 
permitted by the complex cytokine network, that operates at the beginning of the infection. HCV 
interferes with cytokines at various levels and escapes immune response through the induction of a 
Th2/Tc2 cytokine profile. A predominance of the Th1 immune response (and related cytokines) has 
been shown in CHC and in HCV+EHMs. IFN-γ and IFN-γ-inducible CXCL9, -10 and -11 chemokines 
recruit inflammatory infiltrates into the liver parenchyma owing to the inability to control the infection 
process, causing sustained liver damage and eventually liver cirrhosis. “The most important systemic 
HCV-related extrahepatic diseases — MC, lymphoproliferative disorders, diabetes and AITDs — are 
linked to a complex dysregulation of the cytokine/chemokine network” and involve pro-inflammatory 
and Th1 chemokines. Viral clearance may be the outcome of therapeutical administration of cytokines 
such as IFN-α during persistent infection, reverting this process. “Several studies have reported IL-28B 
polymorphisms, and circulating CXCL10, as prognostic markers for HCV treatment efficacy in HCV 
infection. Clinical studies assessing safety and efficacy in the treatment of HCV with exogenous IFN-
λ3 are ongoing”. Several studies have also shown that HCV clearance by DAAs therapy decreases 
circulating CXCL10 levels.  
“Theoretically agents that selectively neutralize CXCL10 could increase patient responsiveness to 
traditional IFN-based HCV therapy”, simultaneously reducing inflammatory immune cell activation. 
For example, specific inhibitors of the CXCR3A could prevent excessive activation of CD8+ Tc cells 
and NK cells that lead to excessive hepatocyte death, limiting Kupffer cells and hepatic stellate cells 
activation and delaying or preventing development of fibrosis. 
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